REFERENCES
- Lidegaard Ø, Nielsen LH, Skovlund CW, . Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 2011;343: d6423.
- Mintzes B, Morgan S, Bassett KL. Medicine by media: Did a critical television documentary affect the prescribing of cyproterone-estradiol (Diane-35)?CMAJ 2005;173:1313–5. (Authors’ note: the title of this paper does indeed mention estradiol, instead of ethinylestradiol.)
- Erdmann D, Schindler EM, Schindler AE. [Ovarian suppression with Diane 35/50]. Geburtshilfe Frauenheilkd 1994;54:627–33. [In German]
- Murcia JM, Esparza ML. [Case report article: ovulation and Diane-35, current perspectives in detection and control of fertility]. Rev Med Univ Navarra 2006;50:26–9. [In Spanish]
- Bruni V, Dei M. Hyperandrogenic conditions in the adolescent. In Amy JJ, ed.Paediatric and adolescent gynaecology. Amsterdam: Elsevier 2003:163–77.
- Martin KA, Chang RJ, Ehrmann DA, . Evaluation and treatment of hirsutism in premenopausal women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1105–20.
- Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003;4: CD001125.
- Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012;7:CD004425.
- van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, . The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339: b2921.
- Martínez F, Ramírez I, Pérez-Campos E, . Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care 2012;17:7–29.
- Raps M, Helmerhorst F, Fleischer K, . Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost 2012; 10:992–7.
- Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, . Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004;2:1594–600.